Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MST1R | Q04912 | 5/20 | 0.45 |
| ▸ | MET | P08581 | 18/20 | 0.40 |
| ▸ | KDR | P35968 | 17/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13166757 | 0.94 | MST1R (0.50) | MST1RMETKDRNTRK1KIT | |
| SCHEMBL10164575 | 0.93 | MET (0.40) | MST1RMETKDR | |
| SCHEMBL2670660 | 0.92 | MET (0.43) | MST1RMETKDR | |
| SCHEMBL2670656 | 0.92 | MET (0.43) | MST1RMETKDR | |
| SCHEMBL13664104 | 0.89 | MST1R (0.47) | MST1RMETKDRNTRK1KIT | |
| SCHEMBL3575098 | 0.87 | MET (0.45) | MST1RMETKDRPOLBMAPT | |
| SCHEMBL3575102 | 0.87 | MET (0.45) | MST1RMETKDRPOLBMAPT | |
| SCHEMBL1478778 | 0.86 | MST1R (0.49) | MST1RMETKDRNTRK1KIT | |
| SCHEMBL10202341 | 0.85 | MST1R (0.45) | MST1RMETKDR | |
| SCHEMBL171881 | 0.85 | MST1R (0.50) | MST1RMETKDRNTRK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| WO-2009026717-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MST1R 104/4885MET 3/4885KDR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.